Company profile
Drugs Made In America Acquisition II Corp. Unit
NASDAQ: DMIIU · Financial Services · Shell Companies
#1 of 1,013 Financial Services companies by revenue
EA Score
——FH 56DQ —GM —SS 31
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, market scale · ↓ workforce scale, listing tenure
Methodology →Revenue TTM
—
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$4.2M
Employees
2
as of 2026-08-01
Market cap
$705.9M
as of 2026-08-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income$4.2M$4.2M2025
Operating income-$488.4k-$488.4k2025
Total assets$505.0M$505.0M2025
Liabilities$17.8M$17.8M2025
Equity-$17.8M-$17.8M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Drugs Made In America Acquisition II Corp. Unit’s financial profile?
Drugs Made In America Acquisition II Corp. Unit earned $4.2M in FY2025 net income.
Peers · Financial Services
Lincoln International Inc.——Velocity Financial, Inc.——SLR Investment Corp.——VersaBank——Peoples Financial Services Corp.——Coastal Financial Corporation——Neighbors
Broward →Key facts
CEORoger Bendelac
SectorFinancial Services
IndustryShell Companies
HeadquartersFort Lauderdale, FL
ExchangeNASDAQ: DMIIU
Employees2
IPO date2025-09-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.